Showing 49 results
November 2018
-
Media Release
World’s first migraine-specific prevention treatment now available in Singapore as Health Sciences Authority approves Novartis Aimovig®
World’s first migraine-specific prevention treatment now available in Singapore as Health Sciences Authority approves Novartis Aimovig® Close to 1 in 10 of the Singapore population suffers from… -
Story Education & Awareness
Experiencing migraine stigma in the workplace
Fight migraine stigma in the workplace.
-
Featured News
Helping to shape the future of healthcare in Asia
Creating business models that can strengthen public health systems in Asia for the long-term.
-
Media Release
New social experiment by Novartis encourages Singaporeans to #StartAskin’ to get clear about psoriasis
New social experiment by Novartis encourages Singaporeans to #StartAskin’ to get clear about psoriasis It is estimated that 40,000 Singaporeans are living with psoriasis - one of the top ten most… -
Story Education & Awareness
#StartAskin’ to get clear about psoriasis
A social experiment was conducted to test Singaporeans’ attitudes towards the skin condition psoriasis.
August 2018
-
Story Education & Awareness
Mona’s story: battling advanced breast cancer
In Singapore, 910 Singaporean women were diagnosed with advanced or Stage IV metastatic breast cancer between 2011 and 2015.
-
Story Education & Awareness
Chris’s story: Battling advanced breast cancer
Around the world, an estimated 250,000 women are diagnosed with advanced breast cancer each year.
July 2018
-
Media Release
Health Sciences Authority approves Novartis Kisqali® for the treatment of Stage IV metastatic breast cancer in postmenopausal women
Health Sciences Authority approves Novartis Kisqali® for the treatment of Stage IV metastatic breast cancer in postmenopausal women Kisqali (LEE011/ Ribociclib), a CDK4/6 inhibitor, in combination… -
In The News
HSA approves Novartis Kisqali
